Week in Review: Shanghai CARsgen to Raise $400 Million in Hong Kong IPO

Deals and Financings   Shanghai CARsgen Therapeutics is staging a Hong Kong IPO that could raise $400 million to support its portfolio of CAR-T candidates; Dingdang Health, a  Beijing  online-offline healthcare company, completed a $220 million financing round; Shanghai Nuance Pharma acquired greater  China  rights to a novel COPD treatment from London's Verona Pharma in a $219 million deal; Ambrx, a San Diego-Shanghai biotech, filed for a US IPO that is expected to raise $100 million for its antibody-drug conjugate and bispecific candidates;   Trials and Approvals   Beijing 's BeiGene said its BTK candidate outperformed AbbVie's Imbruvica in a China Phase III leukemia/lymphoma trial; Suzhou Innovent Bio and HutchMed announced their combination therapy successfully completed an early trial in colorectal cancer patients; CBMG Holdings, a US-China immunotherapy company, said its novel bi-specific CAR-T candidate was effective in an early-stage  China  lymphoma trial; Ascentage Pharma, a  Suzhou  company, reported its Bcl-2 inhibitor was effective in an early trial among patients with hematologic malignancies; Innovent Bio of  Suzhou  and Nanjing IASO Bio posted positive data from a Phase I trial of their CAR-T therapy in multiple myeloma patients; Shanghai OriginCell presented encouraging data from an on-going trial of its GPC3 CAR-T cell therapy in patients with hepatocellular carcinoma; Hangzhou 's Ascletis Pharma was approved to conduct China trials of an oral farnesoid X receptor agonist in chronic hepatitis B patients.  Stock Symbols: (NSDQ: BGNE; HK: 06160) (HK: 01801) (NSDQ/AIM: HCM) (HK: 6855) (HK: 1672) Share this with colleagues: // //